Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?

• Register: ClinicalTrials.gov
• Last refreshed on: 7 November 2016
• Main ID: NCT02309567
• Date of registration: 25/11/2014
• Prospective Registration: No
• Primary sponsor: Cumhuriyet University
• Public title: Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
• Date of first enrolment: May 2014
• Target sample size: 146
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT02309567
• Study type: Observational
• Study design: Observational Model: Case Control, Time Perspective: Prospective
• Phase: N/A

Countries of recruitment

Turkey

Key inclusion & exclusion criteria

Inclusion Criteria:

- patients who were referred to our department with the purpose of 18F-FDG PET/CT
imaging for staging due to lung cancer diagnosis

- patients who were performed 18F-FDG PET/CT for diagnosis in the cause of the
suspected pulmonary nodule/lesion in thorax CT but not detected pathologic FDG
accumulation

- In the control group, healthy subjects with no history of cancer and without any
complaint

Exclusion Criteria:

- Patients had operated for lung cancer, received prior chemotherapy or radiotherapy
for lung cancer, with no definitive histological diagnosis, and a blood glucose level
greater than 150 mg/dL



Age minimum: N/A
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Gene, p53

Lung Neoplasms

Intervention(s)

Other: Blood Collection

Primary Outcome(s)

Serum anti-p53 antibody level measurement. [Time Frame: Blood samples for serum anti-p53 antibody will taken before the FDG administration. All serum will immediately frozen and stored. Analysis will performed presumably after 3 months.]

Secondary ID(s)

T-597

Source(s) of Monetary Support

Please refer to primary and secondary sponsors